The Difference Between Ofatumumab and Otuzumab

Ofatumumab and Obinutuzumab are two different drugs used to treat different types of diseases. Although they are both monoclonal antibodies, they have some obvious differences in indications, mechanisms of action and clinical applications.

Ofatumumab mainly inhibits the activity of B cells by binding to CD20 receptors, thereby reducing disease-related immune responses and inflammation. Ofatumumab is indicated for the treatment of multiple sclerosis (MS), particularly in patients who have failed to respond to other disease-modifying treatments. It is also indicated for the treatment of chronic lymphocytic leukemia (CLL), and can be used with another drug called chlorambucil. Ofatumumab is usually given after other drugs have been tried but have failed. Otuzumab combines with type II CD20 antibodies, making Otuzumab have higher antibody-dependent cytotoxicity induction and higher direct cytotoxic effect than classic CD20 antibodies. It can be used in combination with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It is a humanized monoclonal antibody.

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.